Edwards Lifesciences (EW) EBT (2009 - 2026)

Edwards Lifesciences' EBT history runs 18 years deep, the most recent figure standing at $459.0 million for Q1 2026.

• On a quarterly basis, EBT rose 5.78% year-over-year to $459.0 million in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 19.42% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, down 17.78% from the prior year.
• EBT climbed to $459.0 million in Q1 2026 per EW's latest filing, from $90.4 million in the prior quarter.
• Across five years, EBT topped out at $464.7 million in Q2 2022 and bottomed at $90.4 million in Q4 2025.
• The 5-year median for EBT is $390.1 million (2024), against an average of $366.4 million.
• Across the five-year window, EBT surged 73.7% in 2023 and tumbled 76.83% in 2025, its largest moves.
• Year by year, EBT stood at $211.4 million in 2022, then soared by 73.7% to $367.2 million in 2023, then increased by 6.24% to $390.1 million in 2024, then tumbled by 76.83% to $90.4 million in 2025, then surged by 407.74% to $459.0 million in 2026.
• Per Business Quant, the three latest EW EBT figures stand at $459.0 million (Q1 2026), $90.4 million (Q4 2025), and $348.4 million (Q3 2025).